UnitedHealthcare’s Benefit Assist® program, powered by artificial intelligence, has delivered nearly four times more supplemental cash benefits to eligible members compared to peer plans. Since its launch in early 2025, the capability has identified and processed over 150,000 qualifying events—such as accidents and serious diagnoses—streamlining benefit distribution that historically took weeks of manual review. Early internal metrics indicate a 35% reduction in claim adjudication time and a 22% increase in member satisfaction scores related to out-of-pocket relief.

In the fourth quarter of 2025, UnitedHealth Group reported adjusted earnings of $2.11 per share—down from $6.81 a year earlier—but narrowly beat consensus forecasts by one cent. Revenues rose 12% year-over-year to $113.215 billion, slightly below the Street’s $113.817 billion estimate. CEO Stephen Hemsley highlighted improved core performance and resilience when announcing a 2026 outlook calling for adjusted earnings in excess of $17.75 per share (consensus $17.74) and GAAP earnings of $17.10. The company sees full-year sales topping $439 billion versus analysts’ aggregate projection of $454.6 billion.

UnitedHealth’s share price plunged roughly 20% in late January, erasing tens of billions in market capitalization after the Centers for Medicare & Medicaid Services proposed a meager 0.09% increase in 2027 Medicare Advantage rates. That move, coupled with management’s forecast of a 2% revenue decline due to rising medical costs, fueled one of the steepest single-day drops in the company’s history. Investors have pointed to margin pressures in both the UnitedHealthcare and Optum segments as the primary drivers of the sell-off.

Despite the sell-off, several firms view the downturn as a buying opportunity. Cantor Fitzgerald reiterated an Overweight rating with a $440 target, citing confidence in 2026 EPS guidance of $17.86 and anticipated margin expansion in UnitedHealthcare. The firm expects Optum Health’s strategic refocus to contribute to a return to a 5.5% EBIT margin and deliver $1 billion in annual operating-expense savings via AI-driven efficiency gains. UBS, Oppenheimer and RBC Capital each maintained Buy or Outperform ratings—while trimming price targets—to reflect continued faith in long-term growth prospects.